Oral drops

Oral drops 2.5 mg/mL (ofc) Little Colds Decongestant for Infants Children (Vetco)... 

Oral drops 40 mg/mL (ofc) Infants Motrin (McNeil), PediaCare Fever (Pharmacia)... 

Pseudoephedrine Hydrochloride, Carbinoxamine Maleate Oral Drops... 

Anionic Sodium lauryl sulfate 2-Naphthalene sulfonate sodium Oral drops, granules Oral suspension (see Table 5) (see Table 5)... 

Sodium lauryl sulfate, Sulfuric acid monododecyl ester sodium salt (oral drops)... 

The expressed sap of Dionaea muscipula, a fly-catching plant (Venus flytrap), was once available in Germany as an herbal oncolytic in the form of ampoules and oral drops (1). However, when it became apparent that intramuscular administration could produce shivers, fever, and anaphylactic shock, the health authorities banned the ampoules. They also ruled that the product information on the oral drops should warn against use in pregnancy and should list reddening of the face, headache, dyspnea, nausea, and vomiting as adverse effects. 

Povidone can be used in oral drops, oral solutions, syrups and in topical solutions to improve the solubility of active substances in the same way as in parenteral dosage forms. The medium and higher molecular weight grades, are usually used for this purpose, as they increase the viscosity of the solutions, which can be an advantage in providing a constant drip rate or improving the appearance or the adhesion to the skin. 

The medium-molecular povidones and above all the high-molecular grade, povidone K 90 are used as thickeners in oral and topical solutions and suspensions (viscosity curves, see Section 2.2.3). The use of povidone in suspensions is described in Section 2.4.6. The thickening effect can also be used to adjust the viscosity of solutions - oral drops, eye drops, solutions and syrups - to give a particular drip or flow rate. The thickening effect reduces diffusion processes in the solution, improving the stability of some active substances. 

European Pharmacopoeia 6.0 2008, 01/2008 2264 corrected 6.0, 2625. Public Assessment Report Kaloba Oral Drops, Solution. THR 05332/0003. Medicines and Healthcare prodncts Regulatory Agency, 2008. Accessible from http //www.mhra.gov.nk/. 

Placebo-controlled studies In a double-blind, randomized, placebo-controlled trial for 4 weeks in 367 patients with functional constipation, sodium picosulfate 10 mg/day as oral drops was more efficacious in controlling both bowel movements and symptoms associated with constipation [90. The most frequent adverse event was diarrhea, which occurred in 4.5% of the placebo group and 32% of those who took sodium picosulfate. Abdominal pain was reported by 2.2% of patients on placebo and by 5.6% of patients on sodium picosulfate. 

Ferrous chloride oral drops had been removed from the Dutch formulary as there are now sufficient alternatives like Ferrous fumarate oral suspension 20 mg/ml as a licensed pharmaceutical preparation. That product however is so viscous that a small volume, which is necessary for young children, cannot be measured accurately. In the FNA therefore a Ferrous chloride oral solution 45 mg/ml has been reintroduced. This oral solution contains 20 mg iron (II) per ml which is suitable for children and it is not viscous. 

Powders for the preparation of oral drops generally conform to the definition of Oral powders. They may contain excipients to facilitate dissolution or suspension in the prescribed liquid or to prevent caking. After dissolution or suspension, they comply with the requirements for oral drops. 

Some liquid oral medicines are dosed in drops. This may be practical but the doses that are administered in the form of drops should meet the requirements for uniformity of weight and content. For pharmacy preparations the requirements for oral drops of the Ph. Eur. cannot be achieved with the available dropper devices. See further Sect. 24.4.19.4—6. 

Citalopram can be obtained as both the hydrochloride and hydrobromide salts. The hydrochloride salt is available as oral drops at 40 mg/mL. Tablets (10, 20 and 40 mg)... 

---